Last reviewed · How we verify

NCT04145843

Treatment Outcomes in Bile Duct Stones

Completed Last updated 12 July 2023
What this trial tests

trial testing endoscopic retrograde cholangiopancreatography in Gallstone in 42 participants. Completed in 5 April 2022.

Timeline
6 November 2019
Primary endpoint
5 April 2022
5 April 2022

Quick facts

Lead sponsorAdventHealth
StatusCompleted
Study typeOBSERVATIONAL
Enrollment42
Start date6 November 2019
Primary completion5 April 2022
Estimated completion5 April 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

AdventHealth — full company profile →

Who can join

18 and older, any sex, with Gallstone or Bile Duct Obstruction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This registry is to evaluate the procedural and clinical outcomes in patients undergoing endoscopic treatment of bile duct stones when utilizing an algorithmic management approach.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of endoscopic retrograde cholangiopancreatography

Trials testing the same drug.

Other recruiting trials for Gallstone

Currently open trials in the same condition.

Other AdventHealth trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04145843.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing